Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia
Year: 2019
Type: article
Study design: Observational Study
Abstract: INTRODUCTION AND AIMS: It is not known if the reduction in ED use during periods of OAT occurs across urgent and low acuity presentations. We aimed to compare the incidence and costs of urgent and low acuity ED presentations of people with opioid use disorder (OUD) in and out of opioid agonist treatment (OAT). DESIGN AND METHODS: This was a retrospective cohort study (N=24,875), using linked administrative health data from New South Wales (NSW), Australia. Urgent and low acuity ED incidence and associated costs were calculated for periods in and out of OAT. GEE models estimated the adjusted incidence rate ratio (IRR) for ED presentations. Average costs per person-day were calculated with bootstrap confidence intervals. RESULTS: Incidence of urgent presentations was lower in OAT compared to out of OAT [IRR (95%CI): 0.65 (0.61-0.69)]. In major cities, low acuity presentations were lower during OAT compared to timeout of OAT [IRR (95%CI): 0.82 (0.70-0.96)], in regional/remote areas, low acuity presentations were higher during OAT [IRR (95%CI): 2.65 (1.66-4.21)]. In major cities, average costs for low acuity presentations in OAT were 28% lower atA$0.50 (95%CI: A$0.48-A$0.52) and A$0.69 (95%CI: A$0.66-A$0.71) out of OAT, but 103% higher in regional/remote NSW, at A$2.12 (95%CI: A$1.91-A$2.34) in OAT and A$1.04 (95%CI: A$0.91-A$1.16) out of OAT. DISCUSSION AND CONCLUSIONS: OAT was associated with reductions in urgent ED presentations and associated costs among people with OUD. Geographical variation was evident for low acuity ED presentations, highlighting the need to increase access to OAT in regional/remote areas.
Source: Drug and Alcohol Review
DOI: 10.1111/dar.12976
Authors: Nicola R. Jones, Marian Shanahan, Timothy Dobbins, Louisa Degenhardt, Mark Montebello, Natasa Gisev, Sarah Larney
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Pfizer, AbbVie, Indivior, Australian Government, University of New South Wales, Department of Health and Aged Care, Australian Government, NSW Ministry of Health, Seqirus, National Health and Medical Research Council, National Drug and Alcohol Research Centre, National Institute on Drug Abuse
Awards: G4541530698, Using existing data to understand and ameliorate risk in opioid agonist therapy, Increasing global and national knowledge about illicit drug use, harms and effective interventions, Increasing knowledge about substance use, mental health and harms, and interventions to prevent and reduce harm
OpenAlex ID: W2977858538
